CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology firm targeted on unlocking the broad potential of RNA medicines to remodel human well being, will announce interim knowledge from the continued Section 1 INLIGHT medical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA utilizing Wave’s proprietary SpiNA design, for the remedy of weight problems on Monday, December 8, 2025. A press launch asserting the interim knowledge will likely be issued at 7:30 a.m. ET, adopted by an investor convention name and webcast at 8:30 a.m. ET.
A webcast of the convention name will be accessed by visiting “Investor Occasions” on the investor relations part of the Wave Life Sciences web site: https://ir.wavelifesciences.com/events-publications/occasions. Following the dwell occasion, an archived model of the webcast will likely be out there on the Wave Life Sciences web site.
About WVE-007
WVE-007 is an investigational GalNAc-siRNA that makes use of Wave’s best-in-class proprietary oligonucleotide chemistry and the corporate’s Stereopure interfering Nucleic Acid (SpiNA) subsequent era siRNA design. WVE-007 is designed to silence INHBE mRNA, an weight problems goal with sturdy proof from human genetics. People who’ve a protecting loss-of-function variant in a single copy of the INHBE gene have a more healthy physique composition and cardiometabolic profile, together with much less visceral fats and decrease danger of sort 2 diabetes or heart problems. In preclinical fashions, INHBE GalNAc-siRNA led to adipocyte shrinkage, fewer pro-inflammatory macrophages, much less fibrosis, and improved insulin sensitivity in visceral adipose tissue, supporting potential for metabolic enchancment. As an add-on to semaglutide, Wave’s GalNAc-siRNA doubled weight reduction in mice and prevented weight regain upon cessation of semaglutide.
Concerning the INLIGHT Scientific Trial
INLIGHT is an ongoing, first-in-human medical trial (3:1 energetic: placebo) evaluating WVE-007 in adults residing with obese or weight problems and assesses security, tolerability, pharmacokinetics, Activin E, physique weight and composition, and biomarkers of metabolic well being. INLIGHT is at the moment ongoing at a number of trial websites, together with within the US.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology firm targeted on unlocking the broad potential of RNA medicines to remodel human well being. Wave’s RNA medicines platform, PRISM®, combines a number of modalities, chemistry innovation and deep insights in human genetics to ship scientific breakthroughs that deal with each uncommon and customary issues. Its toolkit of RNA-targeting modalities contains modifying, splicing, RNA interference, and antisense silencing, offering Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally handle illness biology. Wave’s diversified pipeline contains medical applications in weight problems, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s illness, in addition to a number of preclinical applications using the corporate’s broad RNA therapeutics toolkit. Pushed by the calling to “Reimagine Doable,” Wave is main the cost towards a world by which human potential is not hindered by the burden of illness. Wave is headquartered in Cambridge, MA. For extra data on Wave’s science, pipeline and other people, please go to www.wavelifesciences.com and comply with Wave on X and LinkedIn.
Leave a Reply